Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Your scribe thought it was a country song but research suggests the lyrics invading his brain come from the British rock ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Chiefs Hall of Honor member Art Still is a proud foot soldier in the Amyloidosis Army, a nonprofit he started hoping to educate others about the under-reported yet common disease.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...

Taking place on February 14-16, 2025, in Washington, the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient conference is an interdisciplinary and ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...